Concurrent use of mifepristone and misoprostol for early medical abortion

Taiwan J Obstet Gynecol. 2006 Dec;45(4):325-8. doi: 10.1016/S1028-4559(09)60252-7.

Abstract

Objective: This study was designed to evaluate the efficacy of using mifepristone and misoprostol concurrently for early medical abortion.

Materials and methods: A total of 90 women with undesired pregnancies <or= 49 days' gestation were enrolled. All women concurrently received oral mifepristone 200 mg and vaginal misoprostol 800 microg. Follow-up evaluation with transvaginal ultrasonography was performed 4 days and 2 weeks after treatment.

Results: The complete abortion rate was 97.8% (88/90 women). The mean induction to abortion interval was 5.5 hours. The mean bleeding duration was 11.8 days. Patients found the side effects acceptable and reported a 91.1% (82 patients) satisfaction rate.

Conclusion: Concurrent administration of oral mifepristone and vaginal misoprostol is an efficacious regimen for medical abortion of pregnancies <or= 49 days of gestation.

Publication types

  • Clinical Trial

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Abortifacient Agents, Nonsteroidal / adverse effects
  • Abortifacient Agents, Steroidal / administration & dosage*
  • Abortifacient Agents, Steroidal / adverse effects
  • Abortion, Induced / methods*
  • Administration, Intravaginal
  • Administration, Oral
  • Adolescent
  • Adult
  • Drug Therapy, Combination
  • Female
  • Humans
  • Mifepristone / administration & dosage*
  • Mifepristone / adverse effects
  • Misoprostol / administration & dosage*
  • Misoprostol / adverse effects
  • Pregnancy
  • Pregnancy Trimester, First

Substances

  • Abortifacient Agents, Nonsteroidal
  • Abortifacient Agents, Steroidal
  • Misoprostol
  • Mifepristone